Antineoplastics & Immunomodulators
Oncology
Development/MarketedActive
Key Facts
About Deva Holdings
Founded in 1958, Deva Holdings has grown from a domestic Turkish pharmaceutical player into an internationally recognized, publicly traded generics and API manufacturer. Its strategy is built on vertical integration, a strong R&D focus on bioequivalence, and geographic expansion into over 80 countries. Key achievements include establishing a significant export business, maintaining a diverse portfolio spanning multiple therapeutic areas, and operating a large-scale, end-to-end production infrastructure. The company's mission, 'For lives we add health to...', underscores its commercial focus on affordable, accessible medicine.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |